Cited by 2,056Interstitial Lung Diseases and Idiopathic Pulmonary FibrosisOccupational and environmental lung diseasesTransplantation: Methods and Outcomes

The DOI matches its Crossref record; 98 of the 98 references it cites were found in a registry or an index.

Idiopathic Pulmonary Fibrosis

Lederer, David J., Martinez, Fernando J.·2018·New England Journal of Medicine

DOI 10.1056/nejmra1705751

Open this paper in CoChat — free account

Abstract

Idiopathic pulmonary fibrosis appears to be increasing in incidence. It requires early recognition and intervention with supportive care and pharmacologic agents to forestall its progression. Lung transplantation may be curative.

Integrity signals

Registry

Crossref · 10.1056/nejmra1705751

Cites

98 of 98 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

An Official ATS/ERS/JRS/ALAT Statement: Idiopathic Pulmonary Fibrosis: Evidence-based Guidelines for Diagnosis and Management
Raghu, G., Collard, H. R., Egan, J. J., Martinez, F. J., Behr, J., Brown, K. K., Colby, T. V., Cordier, J.-F., Flaherty, K. R., Lasky, J. A., et al. (2011) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.2009-040gl · Cited by 7,186
Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis
Richeldi, L., du Bois, R. M., Raghu, G., Azuma, A., Brown, K. K., Costabel, U., Cottin, V., Flaherty, K. R., Hansell, D. M., Inoue, Y., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1402584 · Cited by 4,654
A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis.
King, T. E., Bradford, W. Z., Castro-Bernardini, S., Fagan, E. A., Glaspole, I., Glassberg, M. K., Gorina, E., Hopkins, P. M., Kardatzke, D., Lancaster, L., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1402582 · Cited by 3,975
Self-citation
Screening for Lung Cancer: U.S. Preventive Services Task Force Recommendation Statement
Moyer, V. A., & on behalf of the U.S. Preventive Services Task Force* (2013) · Annals of Internal Medicine · doi:10.7326/m13-2771 · Cited by 2,642
Guidelines for Management of Incidental Pulmonary Nodules Detected on CT Images: From the Fleischner Society 2017.
MacMahon, H., Naidich, D. P., Goo, J. M., Lee, K. S., Leung, A. N. C., Mayo, J. R., Mehta, A. C., Ohno, Y., Powell, C. A., Prokop, M., et al. (2017) · Radiology · doi:10.1148/radiol.2017161659 · Cited by 2,491
An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of Idiopathic Pulmonary Fibrosis: An Update of the 2011 Clinical Practice Guideline
Raghu, G., Rochwerg, B., Zhang, Y., Garcia, C. A. C., Azuma, A., Behr, J., Brozek, J. L., Collard, H. R., Cunningham, W., Homma, S., et al. (2015) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201506-1063st · Cited by 1,916
Prednisone, Azathioprine, and N -Acetylcysteine for Pulmonary Fibrosis
The Idiopathic Pulmonary Fibrosis Clinical Research Network (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1113354 · Cited by 1,654
Acute Exacerbation of Idiopathic Pulmonary Fibrosis. An International Working Group Report
Collard, H. R., Ryerson, C. J., Corte, T. J., Jenkins, G., Kondoh, Y., Lederer, D. J., Lee, J. S., Maher, T. M., Wells, A. U., Antoniou, K. M., et al. (2016) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201604-0801ci · Cited by 1,444
Self-citation
Telomerase Mutations in Families with Idiopathic Pulmonary Fibrosis
Armanios, M. Y., Chen, J. J.-L., Cogan, J. D., Alder, J. K., Ingersoll, R. G., Markin, C., Lawson, W. E., Xie, M., Vulto, I., Phillips, J. A., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa066157 · Cited by 1,357
A consensus document for the selection of lung transplant candidates: 2014–an update from the Pulmonary Transplantation Council of the International Society for Heart and Lung Transplantation
Weill, D., Benden, C., Corris, P. A., Dark, J. H., Davis, R. D., Keshavjee, S., Lederer, D. J., Mulligan, M. J., Patterson, G. A., Singer, L. G., et al. (2015) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2014.06.014 · Cited by 1,329
Self-citation

Flagged first, then by citations

Show all 98 references

Research works printed but not linked: 2

Philp CJ, Siebeke I, Clements D, et al. ECM crosslinking enhances fibroblast growth and protects against matrix proteolysis in lung fibrosis. Am J Respir Cell Mol Biol 2017 October 20 (Epub ahead of print).29053339
Parker J, Sawtell R, Gagnon L, et al. PBI-4050 is safe and well tolerated and shows evidence of benefit in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2017;195:A7606-A7606. abstract.

Sorted by citations

Items 201–300 of 1,001

Targeting ferroptosis using Chinese herbal compounds to treat respiratory diseases
Xu, M., Zhang, D., & Yan, J. (2024) · Phytomedicine · doi:10.1016/j.phymed.2024.155738 · Cited by 67
Emerging Roles of Airway Epithelial Cells in Idiopathic Pulmonary Fibrosis
Chakraborty, A., Mastalerz, M., Ansari, M., Schiller, H. B., & Staab-Weijnitz, C. A. (2022) · Cells · doi:10.3390/cells11061050 · Cited by 68
Pirfenidone vs. nintedanib in patients with idiopathic pulmonary fibrosis: a retrospective cohort study
Marijic, P., Schwarzkopf, L., Schwettmann, L., Ruhnke, T., Trudzinski, F. C., & Kreuter, M. (2021) · Respiratory Research · doi:10.1186/s12931-021-01857-y · Cited by 62
Comprehensive review of potential drugs with anti-pulmonary fibrosis properties
Ma, J., Li, G., Wang, H., & Mo, C. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.116282 · Cited by 63
Realveolarization with inhalable mucus-penetrating lipid nanoparticles for the treatment of pulmonary fibrosis in mice
Wang, Y. X., Zhang, J., Liu, Y., Xiao, Y., Han, K. S., Kong, Z., Dong, Y., Yang, Z., Fu, Z., Tang, C., et al. (2024) · Science Advances · doi:10.1126/sciadv.ado4791 · Cited by 68
Efficacy and safety of nintedanib in a Greek multicentre idiopathic pulmonary fibrosis registry: a retrospective, observational, cohort study
Antoniou, K. M., Markopoulou, K., Tzouvelekis, A., Trachalaki, A., Vasarmidi, E., Organtzis, J., Tzilas, V., Bouros, E., Kounti, G., Rampiadou, C., et al. (2020) · ERJ Open Research · doi:10.1183/23120541.00172-2019 · Cited by 62
Sirtuins as endogenous regulators of lung fibrosis: A current perspective
Mazumder, S., Barman, M., Bandyopadhyay, U., & Bindu, S. (2020) · Life Sciences · doi:10.1016/j.lfs.2020.118201 · Cited by 61
Eucalyptol prevents bleomycin-induced pulmonary fibrosis and M2 macrophage polarization
Rui, Y., Han, X., Jiang, A., Hu, J., Li, M., Liu, B., Qian, F., & Huang, L. (2022) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2022.175184 · Cited by 61
Pathological collagen targeting and penetrating liposomes for idiopathic pulmonary fibrosis therapy
Yang, M., Lin, Y.-J., Han, M., Bi, Y., He, X.-Y., Xing, L., Jeong, J., Zhou, T., & Jiang, H. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.09.054 · Cited by 63
Leveraging global multi-ancestry meta-analysis in the study of idiopathic pulmonary fibrosis genetics
Partanen, J., Häppölä, P., Zhou, W., Lehistö, A., Ainola, M., Sutinen, E., Allen, R. J., Stockwell, A., Leavy, O. C., Oldham, J. M., et al. (2022) · Cell Genomics · doi:10.1016/j.xgen.2022.100181 · Cited by 63
Gaps in care of patients living with pulmonary fibrosis: a joint patient and expert statement on the results of a Europe-wide survey
Moor, C. C., Wijsenbeek, M. S., Balestro, E., Biondini, D., Bondue, B., Cottin, V., Flewett, R., Galvin, L., Jones, S., Molina‐Molina, M., et al. (2019) · ERJ Open Research · doi:10.1183/23120541.00124-2019 · Cited by 61
Early decrease in erector spinae muscle area and future risk of mortality in idiopathic pulmonary fibrosis
Nakano, A., Ohkubo, H., Taniguchi, H., Kondoh, Y., Matsuda, T., Yagi, M., Furukawa, T., Kanemitsu, Y., & Niimi, A. (2020) · Scientific Reports · doi:10.1038/s41598-020-59100-5 · Cited by 61
Targeting Alveolar Repair in Idiopathic Pulmonary Fibrosis
Ptasinski, V., Stegmayr, J., Belvisi, M. G., Wagner, D. E., & Murray, L. A. (2021) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2020-0476tr · Cited by 60
Connective Tissue Growth Factor in Idiopathic Pulmonary Fibrosis: Breaking the Bridge
Effendi, W. I., & Nagano, T. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23116064 · Cited by 60
Efficacy of Pirfenidone and Nintedanib in Interstitial Lung Diseases Other than Idiopathic Pulmonary Fibrosis: A Systematic Review
Amati, F., Stainer, A., Polelli, V., Mantero, M., Gramegna, A., Blasi, F., & Aliberti, S. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24097849 · Cited by 61
Real-world safety and effectiveness of pirfenidone and nintedanib in the treatment of idiopathic pulmonary fibrosis: a systematic review and meta-analysis
Kou, M., Jiao, Y., Li, Z., Wei, B., Li, Y., Cai, Y., & Wei, W. (2024) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-024-03720-7 · Cited by 68
Cell-based therapy for idiopathic pulmonary fibrosis
Lu, Q., & El-Hashash, A. H. K. (2019) · Stem Cell Investigation · doi:10.21037/sci.2019.06.09 · Cited by 59
Macrophage-Targeted Lung Delivery of Dexamethasone Improves Pulmonary Fibrosis Therapy via Regulating the Immune Microenvironment
Sang, X., Wang, Y., Xue, Z., Qi, D., Fan, G., Tian, F., Zhu, Y., & Yang, J. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.613907 · Cited by 59
Rare and Common Variants in KIF15 Contribute to Genetic Risk of Idiopathic Pulmonary Fibrosis
Zhang, D., Povysil, G., Kobeissy, P. H., Li, Q., Wang, B., Amelotte, M., Jaouadi, H., Newton, C. A., Maher, T. M., Molyneaux, P. L., et al. (2022) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.202110-2439oc · Cited by 56
Glycolysis Reprogramming in Idiopathic Pulmonary Fibrosis: Unveiling the Mystery of Lactate in the Lung
Yan, P., Liu, J., Li, Z., Wang, J., Zhu, Z., Wang, L., & Yu, G. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms25010315 · Cited by 68
Idiopathische Lungenfibrose – Epidemiologie, Ursachen und klinischer Verlauf
Schäfer, S. C., Funke-Chambour, M., & Berezowska, S. (2020) · Der Pathologe · doi:10.1007/s00292-019-00747-x · Cited by 58
Adenosine at the Interphase of Hypoxia and Inflammation in Lung Injury
Li, X., Berg, N. K., Mills, T., Zhang, K., Eltzschig, H. K., & Yuan, X. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2020.604944 · Cited by 59
A systematic review of blood biomarkers with individual participant data meta-analysis of matrix metalloproteinase-7 in idiopathic pulmonary fibrosis
Khan, F., Stewart, I. D., Saini, G., Robinson, K. A., & Jenkins, G. R. (2021) · European Respiratory Journal · doi:10.1183/13993003.01612-2021 · Cited by 60
Radiologic-pathologic correlation of interstitial lung abnormalities and predictors for progression and survival
Chae, K. J., Chung, M. J., Jin, G. Y., Song, Y. J., An, A. R., Choi, H., & Goo, J. M. (2022) · European Radiology · doi:10.1007/s00330-021-08378-8 · Cited by 58
Inhibition of lung microbiota-derived proapoptotic peptides ameliorates acute exacerbation of pulmonary fibrosis
D’Alessandro‐Gabazza, C. N., Yasuma, T., Kobayashi, T., Toda, M., Abdel-Hamid, A. M., Fujimoto, H., Hataji, O., Nakahara, H., Takeshita, A., Nishihama, K., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-29064-3 · Cited by 60
TREM2 Insufficiency Protects against Pulmonary Fibrosis by Inhibiting M2 Macrophage Polarization
Luo, Q., Deng, D., Li, Y., Shi, H., Zhao, J., Qian, Q., Wang, W., Cai, J., Yu, W., & Liu, J. (2023) · International Immunopharmacology · doi:10.1016/j.intimp.2023.110070 · Cited by 64
YAP/TAZ are crucial regulators of macrophage-mediated pulmonary inflammation and fibrosis after bleomycin-induced injury
Mia, M. M., Ghani, S. A. B. A., Cibi, D. M., Bogireddi, H., Nilanthi, U., Selvan, A., Shiu, W., & Singh, M. K. (2025) · European Respiratory Journal · doi:10.1183/13993003.01544-2023 · Cited by 66
Mortality Trends of Idiopathic Pulmonary Fibrosis in the United States From 2004 Through 2017
Jeganathan, N., Smith, R. A., & Sathananthan, M. (2020) · CHEST Journal · doi:10.1016/j.chest.2020.08.016 · Cited by 58
Nurse-Led Palliative Care Clinical Trial Improves Knowledge and Preparedness in Caregivers of Patients with Idiopathic Pulmonary Fibrosis
Lindell, K. O., Klein, S. J., Veatch, M. S., Gibson, K. F., Kass, D. J., Nouraie, M. S., & Rosenzweig, M. Q. (2021) · Annals of the American Thoracic Society · doi:10.1513/annalsats.202012-1494oc · Cited by 62
Targeting Cpt1a-Bcl-2 interaction modulates apoptosis resistance and fibrotic remodeling
Gu, L., Surolia, R., Larson‐Casey, J. L., He, C., Davis, D., Kang, J., Antony, V. B., & Carter, A. B. (2021) · Cell Death and Differentiation · doi:10.1038/s41418-021-00840-w · Cited by 59
Mucins as a New Frontier in Pulmonary Fibrosis
Ballester, B., Milara, J., & Cortijo, J. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8091447 · Cited by 59
Nicotinamide phosphoribosyltransferase prompts bleomycin-induced pulmonary fibrosis by driving macrophage M2 polarization in mice
Chen, Y., Wang, T., Liang, F., Han, J., Lou, Z., Yu, Y., Li, J., Zhan, T., Gu, Y., Dong, L., et al. (2024) · Theranostics · doi:10.7150/thno.94482 · Cited by 60
Airway Redox Homeostasis and Inflammation Gone Awry: From Molecular Pathogenesis to Emerging Therapeutics in Respiratory Pathology
Checa, J., & Aran, J. M. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21239317 · Cited by 55
Metabolic reprogramming of pulmonary fibrosis
Li, J., Zhai, X., Sun, X., Cao, S., Yuan, Q., & Wang, J. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.1031890 · Cited by 63
Small GTPase RAB6 deficiency promotes alveolar progenitor cell renewal and attenuates PM2.5-induced lung injury and fibrosis
Yang, L., Liu, G., Li, X., Xia, Z., Wang, Y., Lin, W., Zhang, W., Zhang, W., & Li, X. (2020) · Cell Death and Disease · doi:10.1038/s41419-020-03027-2 · Cited by 56
Genetic Risk Factors for Idiopathic Pulmonary Fibrosis: Insights into Immunopathogenesis
Michalski, J. E., & Schwartz, D. A. (2021) · Journal of Inflammation Research · doi:10.2147/jir.s280958 · Cited by 61
Identification of a missense variant in SPDL1 associated with idiopathic pulmonary fibrosis
Dhindsa, R. S., Mattsson, J., Nag, A., Wang, Q., Wain, L. V., Allen, R. J., Wigmore, E. M., Ibáñez, K., Vitsios, D., Deevi, S. V. V., et al. (2021) · Communications Biology · doi:10.1038/s42003-021-01910-y · Cited by 56
Phase 2 trial design of BMS-986278, a lysophosphatidic acid receptor 1 (LPA1) antagonist, in patients with idiopathic pulmonary fibrosis (IPF) or progressive fibrotic interstitial lung disease (PF-ILD)
Corte, T. J., Lancaster, L., Swigris, J. J., Maher, T. M., Goldin, J. G., Palmer, S. M., Suda, T., Ogura, T., Minnich, A., Zhan, X., et al. (2021) · BMJ Open Respiratory Research · doi:10.1136/bmjresp-2021-001026 · Cited by 59
Short-Term Effects of Comprehensive Pulmonary Rehabilitation and its Maintenance in Patients with Idiopathic Pulmonary Fibrosis: A Randomized Controlled Trial
Jarosch, I., Schneeberger, T., Gloeckl, R., Kreuter, M., Frankenberger, M., Neurohr, C., Prasse, A., Freise, J., Behr, J., Hitzl, W., et al. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9051567 · Cited by 55
LncRNA Hoxaas3 promotes lung fibroblast activation and fibrosis by targeting miR-450b-5p to regulate Runx1
Lin, S., Zhang, R., Xu, L., Ma, R., Xu, L., Zhu, L., Hu, J., & An, X. (2020) · Cell Death and Disease · doi:10.1038/s41419-020-02889-w · Cited by 56
Pulmonary toxicants and fibrosis: innate and adaptive immune mechanisms
Malaviya, R., Kipen, H. M., Businaro, R., Laskin, J. D., & Laskin, D. L. (2020) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2020.115272 · Cited by 58
Hermansky–Pudlak syndrome pulmonary fibrosis: a rare inherited interstitial lung disease
Yokoyama, T., & Gochuico, B. R. (2021) · European Respiratory Review · doi:10.1183/16000617.0193-2020 · Cited by 56
Exposure to PM2.5 is a risk factor for acute exacerbation of surgically diagnosed idiopathic pulmonary fibrosis: a case–control study
Tahara, M., Fujino, Y., Yamasaki, K., Oda, K., Kido, T., Sakamoto, N., Kawanami, T., Kataoka, K., Egashira, R., Hashisako, M., et al. (2021) · Respiratory Research · doi:10.1186/s12931-021-01671-6 · Cited by 63
Asporin Promotes TGF-β–induced Lung Myofibroblast Differentiation by Facilitating Rab11-Dependent Recycling of TβRI
Huang, S., Lai, X., Yang, L., Ye, F., Huang, C., Qiu, Y., Lin, S., Pu, L., Wang, Z., & Huang, W. (2022) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2021-0257oc · Cited by 55
Galectin 3 enhances platelet aggregation and thrombosis via Dectin-1 activation: a translational study
Chen, Y., Fu, W., Zheng, Y., Yang, J., Liu, Y., Qi, Z., Wu, M., Fan, Z., Yin, K., Chen, Y., et al. (2022) · European Heart Journal · doi:10.1093/eurheartj/ehac034 · Cited by 56
Exosomal microRNAs as Potential Biomarkers and Therapeutic Agents for Acute Ischemic Stroke: New Expectations
Xu, Y., Hu, Y., Xu, S., Liu, F., & Gao, Y. (2022) · Frontiers in Neurology · doi:10.3389/fneur.2021.747380 · Cited by 57
The role of autophagy in idiopathic pulmonary fibrosis: from mechanisms to therapies
Yue, Y.-L., Zhang, M., Liu, J., Fang, L., & Qu, Y.-Q. (2022) · Therapeutic Advances in Respiratory Disease · doi:10.1177/17534666221140972 · Cited by 60
Acute Exacerbation of Idiopathic Pulmonary Fibrosis
Kishaba, T. (2019) · Medicina · doi:10.3390/medicina55030070 · Cited by 55
Prognostic value of transbronchial lung cryobiopsy for the multidisciplinary diagnosis of idiopathic pulmonary fibrosis: a retrospective validation study
Tomassetti, S., Ravaglia, C., Wells, A. U., Cavazza, A., Colby, T. V., Rossi, G., Ley, B., Ryu, J. H., Puglisi, S., Arcadu, A., et al. (2020) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(20)30122-3 · Cited by 55
Mangostanin Derivatives as Novel and Orally Active Phosphodiesterase 4 Inhibitors for the Treatment of Idiopathic Pulmonary Fibrosis with Improved Safety
Huang, Y., Deng, J., Tian, Y., Liang, J., Xie, X. S., Huang, Y., Zhu, J., Zhu, Z., Zhou, Q., He, X., et al. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c01085 · Cited by 52
PEAR1 regulates expansion of activated fibroblasts and deposition of extracellular matrix in pulmonary fibrosis
Geng, Y., Li, L., Yan, J., Liu, K., Yang, A., Zhang, L., Shen, Y., Gao, H., Wu, X., Noth, I., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-34870-w · Cited by 56
Pharmacological effects of baicalin in lung diseases
Wang, D., & Li, Y. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1188202 · Cited by 54
Zinpentraxin Alfa for Idiopathic Pulmonary Fibrosis: The Randomized Phase III STARSCAPE Trial
Richeldi, L., Schiffman, C., Behr, J., Inoue, Y., Corte, T. J., Cottin, V., Jenkins, G. R., Nathan, S. D., Raghu, G., Walsh, S. L. F., et al. (2024) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.202401-0116oc · Cited by 58
Iron-Dependent Mitochondrial Dysfunction Contributes to the Pathogenesis of Pulmonary Fibrosis
Takahashi, M., Mizumura, K., Gon, Y., Shimizu, T., Kozu, Y., Shikano, S., Iida, Y., Hikichi, M., Okamoto, S., Tsuya, K., et al. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.643980 · Cited by 53
Vascular remodelling in idiopathic pulmonary fibrosis patients and its detrimental effect on lung physiology: potential role of endothelial-to-mesenchymal transition
Gaikwad, A. V., Lu, W., Dey, S., Bhattarai, P., Chia, C., Larby, J., Haug, G., Myers, S., Jaffar, J., Westall, G. P., et al. (2022) · ERJ Open Research · doi:10.1183/23120541.00571-2021 · Cited by 52
Idiopathic pulmonary fibrosis (IPF): disease pathophysiology, targets, and potential therapeutic interventions
Saha, P., & Talwar, P. (2023) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-023-04845-6 · Cited by 54
Evaluation and management of Idiopathic Pulmonary Fibrosis
Kishaba, T. (2019) · Respiratory Investigation · doi:10.1016/j.resinv.2019.02.003 · Cited by 51
The contribution of infection and the respiratory microbiome in acute exacerbations of idiopathic pulmonary fibrosis
Invernizzi, R., & Molyneaux, P. L. (2019) · European Respiratory Review · doi:10.1183/16000617.0045-2019 · Cited by 56
The Role of Palliative Care in Reducing Symptoms and Improving Quality of Life for Patients with Idiopathic Pulmonary Fibrosis: A Review
Zou, R. H., Kass, D. J., Gibson, K. F., & Lindell, K. O. (2020) · Pulmonary Therapy · doi:10.1007/s41030-019-00108-2 · Cited by 53
Clinical Molecular Imaging of Pulmonary CXCR4 Expression to Predict Outcome of Pirfenidone Treatment in Idiopathic Pulmonary Fibrosis
Derlin, T., Jäger, B., Jonigk, D. D., Apel, R. M., Freise, J., Shin, H., Weiberg, D., Warnecke, G., Roß, T. L., Wester, H., et al. (2020) · CHEST Journal · doi:10.1016/j.chest.2020.08.2043 · Cited by 51
Therapeutic inhibition of HIF-2α reverses polycythemia and pulmonary hypertension in murine models of human diseases
Ghosh, M. C., Zhang, D., Ollivierre, W. H., Noguchi, A. C., Springer, D., Linehan, W. M., & Rouault, T. A. (2020) · Blood · doi:10.1182/blood.2020009138 · Cited by 54
Targeting Growth Factor and Cytokine Pathways to Treat Idiopathic Pulmonary Fibrosis
Ma, H., Liu, S., Li, S., & Xia, Y. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.918771 · Cited by 55
Pirfenidone facilitates immune infiltration and enhances the antitumor efficacy of PD-L1 blockade in mice
Qin, W., Zou, J., Huang, Y., Liu, C., Kang, Y., Han, H., Tang, Y., Li, L., Liu, B., Zhao, W., et al. (2020) · OncoImmunology · doi:10.1080/2162402x.2020.1824631 · Cited by 52
RETRACTED: Connective tissue disease-related interstitial lung disease (CTD-ILD) and interstitial lung abnormality (ILA): Evolving concept of CT findings, pathology and management
Yoo, H., Hino, T., Han, J., Franks, T. J., Im, Y., Hatabu, H., Chung, M. P., & Lee, K. S. (2020) · European Journal of Radiology Open · doi:10.1016/j.ejro.2020.100311 · Cited by 52
Retracted
Molecular Signatures of Idiopathic Pulmonary Fibrosis
Konigsberg, I. R., Borie, R., Walts, A. D., Cardwell, J., Rojas, M., Metzger, F., Hauck, S. M., Fingerlin, T. E., Yang, I. V., & Schwartz, D. A. (2021) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2020-0546oc · Cited by 52
Incidence and prevalence of idiopathic pulmonary fibrosis: a systematic literature review and meta-analysis
Golchin, N., Patel, A., Scheuring, J., Wan, V., Hofer, K., Collet, J., Elpers, B., & Lesperance, T. (2025) · BMC Pulmonary Medicine · doi:10.1186/s12890-025-03836-1 · Cited by 50
Prostaglandin E2 inhibits profibrotic function of human pulmonary fibroblasts by disrupting Ca2+ signaling
Mukherjee, S., Sheng, W., Michkov, A. V., Sriarm, K., Sun, R., Dvorkin‐Gheva, A., Insel, P. A., & Janssen, L. J. (2019) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00403.2018 · Cited by 50
Recapitulating idiopathic pulmonary fibrosis related alveolar epithelial dysfunction in a human iPSC‐derived air‐liquid interface model
Schruf, E., Schroeder, V., Le, H. Q., Schönberger, T., Raedel, D., Stewart, E. L., Fundel‐Clemens, K., Bluhmki, T., Weigle, S., Schuler, M. J., et al. (2020) · The FASEB Journal · doi:10.1096/fj.201902926r · Cited by 50
Impact of idiopathic pulmonary fibrosis on clinical outcomes of lung cancer patients
Kim, H. C., Lee, S., & Song, J. W. (2021) · Scientific Reports · doi:10.1038/s41598-021-87747-1 · Cited by 51
Targeted Dual Small Interfering Ribonucleic Acid Delivery via Non‐Viral Polymeric Vectors for Pulmonary Fibrosis Therapy
Ji, Q., Hou, J., Yong, X., Gong, G., Muddassir, M., Tang, T., Xie, J., Fan, W., & Chen, X. S. (2021) · Advanced Materials · doi:10.1002/adma.202007798 · Cited by 49
PD-1/PD-L1 inhibitor ameliorates silica-induced pulmonary fibrosis by maintaining systemic immune homeostasis
Zhao, Y., Hao, C., Li, M., Qu, Y., Guo, Y., Deng, X., Si, H., & Yao, W. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.112768 · Cited by 49
Predicting Usual Interstitial Pneumonia Histopathology From Chest CT Imaging With Deep Learning
Bratt, A. K., Williams, J. M., Liu, G., Panda, A., Patel, P. P., Walkoff, L. A., Sykes, A.-M. G., Tandon, Y. K., François, C. J., Blezek, D. J., et al. (2022) · CHEST Journal · doi:10.1016/j.chest.2022.03.044 · Cited by 49
Elevated expression of macrophage MERTK exhibits profibrotic effects and results in defective regulation of efferocytosis function in pulmonary fibrosis
She, Y., Xu, X., Yu, Q., Yang, X., He, J., & Tang, X. X. (2023) · Respiratory Research · doi:10.1186/s12931-023-02424-3 · Cited by 49
Recent progresses of exosome–liposome fusions in drug delivery
Zheng, L., Hu, B., Zhao, D., Liu, W., Liu, Q., Huang, Y., & Ruan, S. (2023) · Chinese Chemical Letters · doi:10.1016/j.cclet.2023.108647 · Cited by 50
Protective effect of peptide DR8 on bleomycin-induced pulmonary fibrosis by regulating the TGF-β/MAPK signaling pathway and oxidative stress
Wang, D., Yan, Z., Bu, L., An, C., Deng, B., Zhang, J., Rao, J., Lu, C. Y., Zhang, J., Zhang, B., et al. (2019) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2019.114703 · Cited by 49
Endoplasmic reticulum stress and glutathione therapeutics in chronic lung diseases
Janssen-Heininger, Y. M. W., Reynaert, N. L., van der Vliet, A., & Anathy, V. (2020) · Redox Biology · doi:10.1016/j.redox.2020.101516 · Cited by 47
Spontaneous Lung Fibrosis Resolution Reveals Novel Antifibrotic Regulators
Tan, Q., Link, P. A., Meridew, J. A., Pham, T. X., Caporarello, N., Ligresti, G., & Tschumperlin, D. J. (2021) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2020-0396oc · Cited by 49
The Burden of Progressive-Fibrosing Interstitial Lung Diseases
Cottin, V., Teague, R., Nicholson, L., Langham, S., & Baldwin, M. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.799912 · Cited by 49
Dynamic atlas of immune cells reveals multiple functional features of macrophages associated with progression of pulmonary fibrosis
Lv, J., Gao, H., Ma, J., Liu, J., Tian, Y., Yang, C., Li, M., Zhao, Y., Li, Z., Zhang, X., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1230266 · Cited by 48
Treatment of Persistent Cough in Subjects with Idiopathic Pulmonary Fibrosis (IPF) with Gefapixant, a P2X3 Antagonist, in a Randomized, Placebo-Controlled Clinical Trial
Martínez, F. J., Afzal, A. S., Smith, J. A., Ford, A. P. D. W., Li, J. J., Li, Y., Kitt, M. M., the Chronic Cough in IPF Study Group, Hussain, I., Sher, M., et al. (2021) · Pulmonary Therapy · doi:10.1007/s41030-021-00162-9 · Cited by 48
Depression and anxiety in patients with interstitial lung disease
Yohannes, A. M. (2020) · Expert Review of Respiratory Medicine · doi:10.1080/17476348.2020.1776118 · Cited by 48
Exosomes derived from induced pluripotent stem cells suppresses M2-type macrophages during pulmonary fibrosis via miR-302a-3p/TET1 axis
Zhou, Y., Gao, Y. J., Zhang, W. Y., Chen, Y., Jin, M., & Yang, Z. (2021) · International Immunopharmacology · doi:10.1016/j.intimp.2021.108075 · Cited by 47
Tissue mechanics coevolves with fibrillar matrisomes in healthy and fibrotic tissues
Dooling, L. J., Saini, K., Anlaş, A. A., & Discher, D. E. (2022) · Matrix Biology · doi:10.1016/j.matbio.2022.06.006 · Cited by 46
Nintedanib Inhibits Endothelial Mesenchymal Transition in Bleomycin-Induced Pulmonary Fibrosis via Focal Adhesion Kinase Activity Reduction
Yu, W.-K., Chen, W., Su, V. Y., Shen, H., Wu, H.-H., Chen, H., & Yang, K. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23158193 · Cited by 48
Inhaled Lipid Nanoparticles Alleviate Established Pulmonary Fibrosis
Li, D., Zhao, A., Zhu, J., Wang, C., Shen, J., Zheng, Z., Pan, F., Liu, Z., Chen, Q., & Yang, Y. (2023) · Small · doi:10.1002/smll.202300545 · Cited by 47
Insights into the Cellular and Molecular Mechanisms behind the Antifibrotic Effects of Nerandomilast
Reininger, D., Wolf, F., Mayr, C. H., Wespel, S. L., Laufhaeger, N., Geillinger‐Kästle, K. E., Dick, A., Gantner, F., Nickolaus, P., & Herrmann, F. E. (2025) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2024-0614oc · Cited by 64
Updates in the field of non-esophageal gastroesophageal reflux disorder
Ghisa, M., Coletta, M. D., Barbuscio, I., Marabotto, E., Barberio, B., Frazzoni, M., de Bortoli, N., Zentilin, P., Tolone, S., Ottonello, A., et al. (2019) · Expert Review of Gastroenterology & Hepatology · doi:10.1080/17474124.2019.1645593 · Cited by 49
Discovery of 4-Methylquinazoline Based PI3K Inhibitors for the Potential Treatment of Idiopathic Pulmonary Fibrosis
Lin, S., Jin, J., Liu, Y., Tian, H., Zhang, Y., Fu, R., Zhang, J., Wang, M., Du, T., Ji, M., et al. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b00969 · Cited by 47
Low-level laser therapy attenuates lung inflammation and airway remodeling in a murine model of idiopathic pulmonary fibrosis: Relevance to cytokines secretion from lung structural cells
de Brito, A. A., da Silveira, E. C., Rigonato‐Oliveira, N. C., Soares, S., Brandão-Rangel, M. A. R., Soares, C. R., Santos, T. G., Alves, C. E., Herculano, K. Z., Vieira, R. P., et al. (2019) · Journal of Photochemistry and Photobiology B Biology · doi:10.1016/j.jphotobiol.2019.111731 · Cited by 50
Transcriptional analysis of lung fibroblasts identifies PIM1 signaling as a driver of aging-associated persistent fibrosis
Pham, T. X., Lee, J., Guan, J., Caporarello, N., Meridew, J. A., Jones, D. L., Tan, Q., Huang, S. K., Tschumperlin, D. J., & Ligresti, G. (2022) · JCI Insight · doi:10.1172/jci.insight.153672 · Cited by 48
Fibroblasts positive for meflin have anti-fibrotic properties in pulmonary fibrosis
Nakahara, Y., Hashimoto, N., Sakamoto, K., Enomoto, A., Adams, T. S., Yokoi, T., Omote, N., Poli, S., Ando, A., Wakahara, K., et al. (2021) · European Respiratory Journal · doi:10.1183/13993003.03397-2020 · Cited by 46
Mechanical forces: The missing link between idiopathic pulmonary fibrosis and lung cancer
Wang, C., & Yang, J. (2022) · European Journal of Cell Biology · doi:10.1016/j.ejcb.2022.151234 · Cited by 49
Systematic review of overlapping microRNA patterns in COVID-19 and idiopathic pulmonary fibrosis
Guiot, J., Henket, M. A., Remacle, C., Cambier, M., Struman, I., Winandy, M., Moermans, C., Louis, E. J., Malaise, M., Ribbens, C., et al. (2023) · Respiratory Research · doi:10.1186/s12931-023-02413-6 · Cited by 48
Trained Immunity for Personalized Cancer Immunotherapy: Current Knowledge and Future Opportunities
Lérias, J. R., de Sousa, E., Paraschoudi, G., Martins, J. D., Condeço, C., Figueiredo, N., Carvalho, C. T., Dodoo, E., Maia, A., Castillo-Martín, M., et al. (2020) · Frontiers in Microbiology · doi:10.3389/fmicb.2019.02924 · Cited by 45
Updated Evaluation of the Safety, Efficacy and Tolerability of Pirfenidone in the Treatment of Idiopathic Pulmonary Fibrosis
Gulati, S., & Luckhardt, T. (2020) · Drug Healthcare and Patient Safety · doi:10.2147/dhps.s224007 · Cited by 45
Asiaticoside might attenuate bleomycin‐induced pulmonary fibrosis by activating cAMP and Rap1 signalling pathway assisted by A2AR
Luo, J., Zhang, T., Zhu, C., Sun, J., Zhu, W., Ai, W., Huang, X., & Wang, X. (2020) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.15505 · Cited by 46
Alveolar Dynamics and Beyond – The Importance of Surfactant Protein C and Cholesterol in Lung Homeostasis and Fibrosis
Sehlmeyer, K., Ruwisch, J., Roldán, N., & López-Rodríguez, E. (2020) · Frontiers in Physiology · doi:10.3389/fphys.2020.00386 · Cited by 46
Serial Measurements of Circulating KL-6, SP-D, MMP-7, CA19-9, CA-125, CCL18, and Periostin in Patients with Idiopathic Pulmonary Fibrosis Receiving Antifibrotic Therapy: An Exploratory Study
Majewski, S., Szewczyk, K., Żal, A., Białas, A. J., Miłkowska-Dymanowska, J., & Piotrowski, W. J. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10173864 · Cited by 46
Extracellular Lipids in the Lung and Their Role in Pulmonary Fibrosis
Burgy, O., Loriod, S., Beltramo, G., & Bonniaud, P. (2022) · Cells · doi:10.3390/cells11071209 · Cited by 50
Colocalization of Gene Expression and DNA Methylation with Genetic Risk Variants Supports Functional Roles of MUC5B and DSP in Idiopathic Pulmonary Fibrosis
Borie, R., Cardwell, J., Konigsberg, I. R., Moore, C. M., Zhang, W. E., Sasse, S. K., Gally, F., Dobrinskikh, E., Walts, A. D., Powers, J., et al. (2022) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.202110-2308oc · Cited by 45

Authors: Lederer, D. J., & Martinez, F. J.
Affiliations: Columbia University Irving Medical Center (US)
From the Departments of Medicine and Epidemiology, Columbia University Irving Medical Center (D.J.L.), and the Department of Medicine, Weill Cornell Medical Center (F.J.M.) — both in New York.
ORCID: Lederer, David J.
Venue: New England Journal of Medicine
Publisher: Massachusetts Medical Society
Published: 2018-05-10
Volume: 378
Issue: 19
Pages: 1811-1823
ISSN: 0028-4793 (ISSN-L)
1533-4406
DOI: 10.1056/nejmra1705751
OpenAlex: W2799479598
Cited by: 2,056
References: 98
Citations by year: 2026: 248 · 2025: 267 · 2024: 299 · 2023: 308 · 2022: 301 · 2021: 266 · 2020: 197 · 2019: 129 · 2018: 40
FWCI: 28.43
Type: journal article
Language: en
Open access: closed
Locations: New England Journal of Medicine (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Occupational and environmental lung diseases
Health Sciences › Medicine › Surgery › Transplantation: Methods and Outcomes
Keywords: idiopathic pulmonary fibrosis, incidence, early recognition, supportive care, pharmacotherapy, disease progression, lung transplantation
MeSH terms: Diagnosis, Differential, Dyspnea, Enzyme Inhibitors, Humans, Indoles, Lung, Oxygen Inhalation Therapy, Prognosis, Pyridones, Risk Factors, Tomography, X-Ray Computed, Transforming Growth Factor beta, Idiopathic Pulmonary Fibrosis

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Idiopathic Pulmonary Fibrosis

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks